期刊文献+
共找到8篇文章
< 1 >
每页显示 20 50 100
Systemic treatments for resectable carcinoma of the esophagus
1
作者 Wattana Leowattana Pathomthep Leowattana Tawithep Leowattana 《World Journal of Gastroenterology》 SCIE CAS 2023年第30期4628-4641,共14页
One of the most prevalent malignancies in the world is esophageal cancer(EC).The 5-year survival rate of EC remains pitiful despite treatment advancements.Neoadjuvant chemoradiotherapy in conjunction with esophagectom... One of the most prevalent malignancies in the world is esophageal cancer(EC).The 5-year survival rate of EC remains pitiful despite treatment advancements.Neoadjuvant chemoradiotherapy in conjunction with esophagectomy is the standard of care for patients with resectable disease.The pathological complete response rate,however,is not acceptable.A distant metastasis or a locoregional recurrence will occur in about half of the patients.To increase the clinical effectiveness of therapy,it is consequently vital to investigate cutting-edge and potent therapeutic modalities.The approach to the management of resectable EC using immunotherapy has been considerably altered by immune checkpoint inhibitors.Systemic immunotherapy has recently been shown to have the potential to increase the survival of patients with resectable EC,according to growing clinical data.A combination of chemotherapy,radiation,and immunotherapy may have a synergistic antitumor impact because,according to mounting evidence,these treatments can stimulate the immune system via a number of different pathways.In light of this,it makes sense to consider the value of neoadjuvant immunotherapy for patients with surgically treatable EC.In this review,we clarify the rationale for neoadjuvant immunotherapy in resectable EC patients,recap the clinical outcomes of these approaches,go through the upcoming and ongoing investigations,and emphasize the difficulties and unmet research requirements. 展开更多
关键词 Systemic treatment Resectable carcinoma of the esophagus Personalized medicine Biomarkers Chemotherapy CHEMORADIOTHERAPY IMMUNOTHERAPY Immune checkpoint inhibitors
下载PDF
CARCINOMA ARISING IN BARRETT'S ESOPHAGUS (A REPORT OF 51 CASES)
2
作者 李辉 姚松朝 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 1995年第4期290-292,共3页
Fifty-one patients with carcinoma arising in Barrett's esophagus were treated surgically from 1971 to 1990. This represented 10.2% of all treated cases with esophageal carcinoma during the same period. The mean ag... Fifty-one patients with carcinoma arising in Barrett's esophagus were treated surgically from 1971 to 1990. This represented 10.2% of all treated cases with esophageal carcinoma during the same period. The mean age was 63 years. The most common symptom was dysphagia. According to PTNM staging, 18 were stage II,3 stage III and 3 stage IV. All patients were treated bysurgery. The 30-day hospital mortality was 3.98%. Theone, two and five-year survival rates were 45.9%, 25.0%and 13.6%, respectively. The 5-year survival rate wassignificantly greater for patrents with stage II (25.0%)than for parients with stage III + IV (4.s%) (P<0.05) andfor tumor length less than 6 cm (21%) than for tumorlength greater than 6 cm (0). The results indicate that thesurvival rate following resection is closely related to theclinical stage and tumor size. 展开更多
关键词 Barrett's esophagus carcinoma of the esophagus Surgery.
下载PDF
Synchronous primary cancers of trachea and esophagus and ventricular tachycardia
3
作者 Wen Luo Guomin Luo +1 位作者 Youling Gong Jin Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第3期345-350,共6页
The incidence of multiple primary cancers involving trachea is rare. We present a case of synchronous double primary cancer of trachea and esophagus in a 70-year-old woman, with a special symptom of ventricular tachyc... The incidence of multiple primary cancers involving trachea is rare. We present a case of synchronous double primary cancer of trachea and esophagus in a 70-year-old woman, with a special symptom of ventricular tachycardia and no/a/story of smoking and alcohol drinking. Biopsies (tom multiple loci demonstrated the patient had primary small cell cancer of trachea and squamous cell carcinoma in situ of esophagus. The patient was successfully treated with four cycles of chemotherapy consisting of etoposide and earboplatin (EC) followed by thoracic radiotherapy (60 Gy in 30 fractions, in 6 weeks), and was evaluated to have complete response of tumor. To our knowledge, there is no synchronous cancer of trachea and esophagus has been reported in English literature, and our experience showed sequential EC chemotherapy and radiotherapy provided an effective treatment to control both cancers. 展开更多
关键词 Synchronous cancer trachea small cell cancer esophagus carcinoma TACHYCARDIA RADIOTHERAPY ehemotherapy
下载PDF
Double tracheal stents reduce side effects of progression of malignant tracheoesophageal fistula treated with immunotherapy: A case report
4
作者 Chang-An Li Wei-Xia Yu +3 位作者 Lin-Yang Wang Hang Zou Cheng-Jun Ban Hong-Wu Wang 《World Journal of Clinical Cases》 SCIE 2022年第11期3527-3532,共6页
BACKGROUND The protective effect of tracheal stents is reported to relieve airway obstruction and reduce side effects of rapid progression of malignant tracheoesophageal fistula(MTEF)after immunotherapy in this case w... BACKGROUND The protective effect of tracheal stents is reported to relieve airway obstruction and reduce side effects of rapid progression of malignant tracheoesophageal fistula(MTEF)after immunotherapy in this case with 10 mo follow-up.CASE SUMMARY Two kinds of silicone stents were placed in the main airway of a 58-year-old male to relieve the airway obstruction caused by advanced esophageal carcinoma.The patient then received four doses of toripalimab.Subsequently,rapid,progressive deterioration of the original fistula was found.Although the fistula enlarged rapidly after immunotherapy,it remained covered completely,and likely because of this,his condition remained stable.Therefore,immunotherapy could be continued to treat the primary tumor.Despite these efforts,the patient died of the advancement of his esophageal cancer.CONCLUSION Appropriately-sized tracheal stent placement combined with immune checkpoint inhibitors may improve the quality of life and survival of patients with MTEF. 展开更多
关键词 IMMUNOTHERAPY Rapid progression Malignant tracheoesophageal fistula esophagus carcinoma Double tracheal stents Case report
下载PDF
胸上中段食管癌后程加速外照射联合腔内放疗的临床分析
5
作者 马红星 《菏泽医学专科学校学报》 2007年第2期17-19,共3页
目的探讨中上段食管癌后程加速外照射联合腔内放疗的疗效。方法112例中上段食管癌患者随机分为56例后程加速超分割放射治疗(后超组),开始常规分割放疗,为5次/周,2.0 Gy/次,总量30 Gy/3周,然后改2次/天,1.5 Gy/次,间隔6小时以上,共2周。5... 目的探讨中上段食管癌后程加速外照射联合腔内放疗的疗效。方法112例中上段食管癌患者随机分为56例后程加速超分割放射治疗(后超组),开始常规分割放疗,为5次/周,2.0 Gy/次,总量30 Gy/3周,然后改2次/天,1.5 Gy/次,间隔6小时以上,共2周。56例后程加速1周,腔内放疗2周(腔内组),腔内放疗采用低剂量率192 Ir,食管黏膜参考点剂量3.0Gy/次,每周一、周五,共2周,总量12 Gy/4次。结果后超组和腔内组近期有效率分别为98.2%1、00%(P>0.05)。3、5年生存率分别为48.2%5、1.7%(P>0.05);35.7%、37.5%(P>0.05),两组无差异显著性,3、5年局部控制率分别为69.6%、73.2%;53.5%、57.1%(P>0.05),两组无差异显著性。结论后程加速联和腔内放疗,能有效控制肿瘤,值得临床应用。 展开更多
关键词 食管肿瘤/放射疗法 放射剂量分次 食管肿瘤/治疗 预后
下载PDF
SUPERFICIAL CARCINOMAS OF THE ESOPHAGUS AND GASTRIC CARDIA A CLINICOPATHOLOGICAL ANALYSIS OF 141 CASES
6
作者 刘俊峰 王其彰 +6 位作者 李保庆 孟宪利 张毓德 杜喜群 严嘉顺 平育敏 李文起 《Chinese Medical Journal》 SCIE CAS CSCD 1995年第10期754-759,共6页
From January 1970 to June 1999, 141 patients with superficial esophageal and cardiac carcinomas (SEC and SCC) underwent surgical treatment, Of the 141 patients 128 (90.8%) had slight symptoms related to swallowing, an... From January 1970 to June 1999, 141 patients with superficial esophageal and cardiac carcinomas (SEC and SCC) underwent surgical treatment, Of the 141 patients 128 (90.8%) had slight symptoms related to swallowing, and the remaining 13 (9.2%) were asymptomatic, Balloon cytology and esophagoscopy proved very useful for the diagnosis of SEC and SCC, and Lugol's solution staining technique was an effective auxiliary diagnostic measure, Lymph node metastasis was not found in patients with epithelial (EP) cancer, However, it was present in one (2.9%) of 34 patients with muscularis mucosal (MM) invasion, and in 5 (8.6%) of 58 patients with submucosal (SM) cancer, The 5-year survival rates of the patients with SEC and SCC were 75.5% and 71.4%, respectively (P > 0.05). The different depth of tumor invasion including EP, MM and SM cancers showed significant differences in the 5-year survival rate (P < 0.05), Although the prognosis for the patients with lymph node metastasis is poor, we should advocate extended lymph node dissection in surgical treatment of the patients in whom MM and SM cancers are suspected. 展开更多
关键词 SCC SEC A CLINICOPATHOLOGICAL ANALYSIS OF 141 CASES SUPERFICIAL carcinomaS OF THE esophagus AND GASTRIC CARDIA
原文传递
Basaloid squamous carcinoma of the esophagus:clinicopathological,immunohistochemical and electron microscopic studies of 16 cases
7
作者 张新华 孙桂勤 +2 位作者 周晓军 郭慧芳 张泰和 《Chinese Medical Journal》 SCIE CAS CSCD 1998年第7期22-22,共1页
Abstract Objective To further clarify the clinicopathological, immunohistochemical and electron microscopic features, and prognostic aspect of a rare esophageal carcinoma, i.e., basaloid squamous carcinoma (BSC)... Abstract Objective To further clarify the clinicopathological, immunohistochemical and electron microscopic features, and prognostic aspect of a rare esophageal carcinoma, i.e., basaloid squamous carcinoma (BSC). Methods The archival materials of 763 cases of esophageal malignancies (1977 1996) from the Dept. of Pathology, General Hospital of Nanjing Military Region, PLA, were reviewed and sixteen cases (2.1%) of BSC were detected. The clinical and pathological features of these cases were evaluated. Immunohistochemistry (S P method), histochemical staining, and electron microscope were utilized to further characterize the neoplasm. Results There were 9 males and 7 females, with a mean age of 58 years. The tumors were classified as stage Ⅰ (n=1), stage ⅡA (n=6), stage ⅡB (n=2), stage Ⅲ (n=5), and stage Ⅳ (n=2) according to the criteria of the UICC TNM classification system of malignant tumors (1987). Most neoplasms in our series were located in the middle third of the esophagus. Grossly, they had an appearance similar to that of conventional esophageal carcinoma. Histologically, they showed a typical cytoarchitectural pattern of BSC. The most important histologic feature of this tumor was that the carcinoma had a basaloid pattern, intimately associated with squamous cell carcinoma, dysplasia, or focal squamous differentiation. The basaloid cells were round or oval in shape with scant cytoplasm. The nuclei showed pleomorphism, hyperchromatin, and numerous mitotic figures. The basaloid cells were arranged mainly in the form of solid, smooth contoured lobules with peripheral palisading. Comedo necrosis in the islands of basaloid cells, small cystic spaces containing Alcian blue or PAS positive material, and PAS positive hyalinized stroma were frequently found. A panel of immunostains were used for the basaloid component of the tumor with the following results: cytokeratin (Pan),14/16 (+); epithelial membrane antigen, 16/16 (+); Vimentin, 4/16 (+); S 100 protein, 7/16 (+). Carcinoembryonic antigen and smooth muscle actin were negative. Electron microscopic (EM) study of 7 cases revealed that the basaloid cells are poorly differentiated, with a few desmosomes and fibrils and numerous free and polyribosome. The microcystic and intertrabecular spaces identified by light microscopy were seen under EM to be lined by basal membranes and filled with either loose reduplicated or compact globoid basal lamina showing fingerprint like pattern. Of the 11 cases with adequate follow up, 8 cases died within 2 years, the average survival time being 16.2 months. No cases of stages Ⅱ, Ⅲ, or Ⅳ survived beyond 5 years. The one year survival rate was 60% and two year 20%. Conclusion It is indicated that the BSC of the esophagus is a distinct clinicopathological entity with poor prognosis. The cellular differentiation and biologic behavior of the esophageal BSC were assumed to be situated between those of conventional squamous cell carcinoma and small cell carcinoma. 展开更多
关键词 Basaloid squamous carcinoma of the esophagus
原文传递
Clinical Application of Modified Anyang Type 2 Esophageal Intubation Instrument──A New Esophageal Intubation Method
8
作者 韩欣 南兆胜 +3 位作者 毛彦普 葛志江 陈茂盛 段瑜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 1995年第3期187-189,共3页
The preliminary experience in the clinical use of Anyang Type 2 esophageal intubation instrument, designed by ourselves, in 11 patients with severe esophageal obstruction due to advanced carcinoma of the esophageal wa... The preliminary experience in the clinical use of Anyang Type 2 esophageal intubation instrument, designed by ourselves, in 11 patients with severe esophageal obstruction due to advanced carcinoma of the esophageal was reported. The diagnosis of all 11 cases was confirmed by bariummeal roentgenography. After intubation, all the patients could take liquid or soft diet by mouth.There was no operative mortality and the patients survived 2 to 14 months (mean5.7 months). All of them could take food by mouth before death. The clinical application proved that the intubation has been a safe and suitable management. 展开更多
关键词 Anyang Type 2 esophageal intubation instrument urethral reunion operation/endoesophageal intubation advanced carcinoma of the esophagus
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部